JAK2 and neoplasm: Depletion of CD8+ T cells significantly reduced the anti-tumor efficacy of triple combination treatment (Fig. 5h) suggesting that CD8+ cytotoxic T cells are critical for anti-tumor efficacy of MEK1/2-JAK2/PDGFRβ inhibition in triple combination therapy.